The Rationale for Potential Pharmacotherapy of COVID-19
On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/5/96 |
| _version_ | 1797568037741658112 |
|---|---|
| author | Maha Saber-Ayad Mohamed A. Saleh Eman Abu-Gharbieh |
| author_facet | Maha Saber-Ayad Mohamed A. Saleh Eman Abu-Gharbieh |
| author_sort | Maha Saber-Ayad |
| collection | DOAJ |
| description | On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use. |
| first_indexed | 2024-03-10T19:49:42Z |
| format | Article |
| id | doaj.art-78c677328cd6461fb629b1d535889f86 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T19:49:42Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-78c677328cd6461fb629b1d535889f862023-11-20T00:27:35ZengMDPI AGPharmaceuticals1424-82472020-05-011359610.3390/ph13050096The Rationale for Potential Pharmacotherapy of COVID-19Maha Saber-Ayad0Mohamed A. Saleh1Eman Abu-Gharbieh2Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAEDepartment of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAEDepartment of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, UAEOn 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use.https://www.mdpi.com/1424-8247/13/5/96COVID-19SARS-CoV-2remdesivirchloroquinelopinavirfavipiravir |
| spellingShingle | Maha Saber-Ayad Mohamed A. Saleh Eman Abu-Gharbieh The Rationale for Potential Pharmacotherapy of COVID-19 Pharmaceuticals COVID-19 SARS-CoV-2 remdesivir chloroquine lopinavir favipiravir |
| title | The Rationale for Potential Pharmacotherapy of COVID-19 |
| title_full | The Rationale for Potential Pharmacotherapy of COVID-19 |
| title_fullStr | The Rationale for Potential Pharmacotherapy of COVID-19 |
| title_full_unstemmed | The Rationale for Potential Pharmacotherapy of COVID-19 |
| title_short | The Rationale for Potential Pharmacotherapy of COVID-19 |
| title_sort | rationale for potential pharmacotherapy of covid 19 |
| topic | COVID-19 SARS-CoV-2 remdesivir chloroquine lopinavir favipiravir |
| url | https://www.mdpi.com/1424-8247/13/5/96 |
| work_keys_str_mv | AT mahasaberayad therationaleforpotentialpharmacotherapyofcovid19 AT mohamedasaleh therationaleforpotentialpharmacotherapyofcovid19 AT emanabugharbieh therationaleforpotentialpharmacotherapyofcovid19 AT mahasaberayad rationaleforpotentialpharmacotherapyofcovid19 AT mohamedasaleh rationaleforpotentialpharmacotherapyofcovid19 AT emanabugharbieh rationaleforpotentialpharmacotherapyofcovid19 |